Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37541792/
The LiRa_NL group showed the most weight loss, although the discontinuation rate was high. Most side-effects occurred at 1-2 months. When prescribing GLP-1 RA, education concerning side-effects and discontinuation is...
Conclusions: The LiRa_NL group showed the most weight loss, although the discontinuation rate was high. Most side-effects occurred at 1–2 months. When prescribing GLP-1 RA, education concerning side-effects and discontinuation is needed to enhance treatment adherence.
Share
Semaglutide and cancer: A systematic review and meta-analysis
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402123001303?via=ihub
French national health care insurance system database has suggested 1-3 years use of glucagon like peptide-1 receptor agonists (GLP1RA) (exenatide, li...
Conclusion: Semaglutide use in RCTs and real-world studies was not associated with an increased risk of any types of cancer, and this conclusion is supported by a high grade of evidence.
Share
Incretin Analogs for Weight Management in Adults Without Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37522468/
All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.
Conclusions: All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.
Share
Conclusions/Relevance: Discontinuation of Ozempic should be considered prior to general anesthesia due to gastrointestinal side effects including delayed gastric emptying. As the popularity of Ozempic grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative consideration.
Share
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
Source : https://www.sciencedirect.com/science/article/abs/pii/S0196978123001365?via=ihub
Novel dual agonists for the glucagon-like peptide-1 (GLP-1) and Y2 receptor hold the potential for enhanced efficacy over GLP-1 receptor (GLP-1R) agon...
Conclusions/Relevance: These results indicate the potential of developing xGLP/PYY-6 as an antiobesity, lipid regulation, antisteatotic, and antidiabetic agent.
Share